Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Recurrence 1Multi-centric Castleman's Disease 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 38Melphalan 20Bortezomib 18Cyclophosphamide 17Calcium Dobesilate 14Filgrastim 13daratumumab 11Peripheral Blood Stem Cell Transplantation 10pomalidomide 9Lenalidomide 8fludarabine phosphate 7dexamethasone acetate 6Whole-Body Irradiation 6Mycophenolic Acid 6Granulocyte Colony-Stimulating Factor 5Cyclosporine 5venetoclax 4ixazomib 4dexamethasone 21-phosphate 4Thalidomide 4Etoposide 4Busulfan 4auricularum 3Tacrolimus 3Radiotherapy 3Focal Adhesion Protein-Tyrosine Kinases 3Epoetin Alfa 3Doxycycline 3Darbepoetin alfa 3Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immunoglobulin Light-chain Amyloidosis × Hyaluronoglucosaminidase × Clear all
NCT06376214 2024-04-19

Daratumumab for Patients With Light Chain Amyloidosis

Nanjing University School of Medicine

Phase NA Recruiting
100 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡